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Clinical signiﬁcance of nuclear non-phosphorylated beta-catenin
in acute myeloid leukaemia and myelodysplastic syndrome
The Wnt/beta-catenin pathway is involved in the self-renewal
and proliferation of haematopoietic stem cells (Reya et al,
2003; Willert et al, 2003). Signaling is initiated by binding of
Wnt proteins to transmembrane receptors of the Frizzeled
family (Giles et al, 2003). In the absence of Wnt signals,
a dedicated complex of proteins that includes the tumor
suppressor gene product APC, axin, and glycogen synthase
kinase-3-beta (GSK3-beta) phosphorylates speciﬁc serine and
threonine residues within the N-terminal region of beta-
catenin, which leads to the ubiquitination of beta-catenin and
its degradation by proteasomes (Conacci-Sorrell et al, 2002;
Noort et al, 2002; Staal et al, 2002; Giles et al, 2003). Wnt
signals block GSK3beta activity, resulting in the accumulation
of non-phosphorylated beta-catenin (NPBC), which is ﬁnally
translocated to the nucleus (Noort et al, 2002; Staal et al,
2002). Nuclear NPBC interacts with T-cell transcription
factor (TCF) and lymphoid enhancer factor (LEF), and it
activates target genes such as MYC and CCND1 (He et al,
1998; Tetsu & Maccormick, 1999). Therefore, nuclear NPBC
is known to be oncogenic in many solid tumors (Bienz &
Clevers, 2000; Polakis, 2000). Mutations of APC, beta-
catenin, or axin, which are observed in various tumors, lead
to stabilization of NPBC (Morin et al, 1997; Barker &
Clevers, 2000).
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Summary
Wnt signaling activates the canonical pathway and induces the accumulation
of non-phosphorylated beta-catenin (NPBC) in the nucleus. Although this
pathway plays an important role in the maintenance of haematopoietic stem
cells as well as in oncogenesis, the signiﬁcance of nuclear NPBC remains
unclear in malignant haematopoiesis. This study examined the expression of
nuclear NPBC in bone marrow specimens from 54 and 44 patients with
de novo acute myeloid leukaemia (AML) and myelodysplastic syndrome
(MDS), respectively. On immunohistochemistry with an anti-NPBC
antibody, the nuclei were positively stained in 22 and 18 of AML and
MDS specimens, respectively. Staining of nuclear NPBC was associated with
AML subtypes (M6 and M7), low complete remission (CR) rate, and poor
prognosis. Nuclear NPBC was also associated with a high score when using
the International Prognostic Scoring System (IPSS) for MDS and with )7/
)7q and complex karyotypes. These ﬁndings suggest that in situ detection of
nuclear NPBC by immunohistochemistry could provide new insights into the
pathogenesis and prognosis of AML and MDS.
Keywords: beta-catenin, non-phosphorylated beta-catenin, acute myeloid
leukaemia, myelodysplastic syndrome, immunohistochemistry.
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catenin pathway and the non-obese severe combined immu-
nodeﬁcient (NOD-SCID)-repopulating capacity of normal
haematopoietic stem cells. They lead to increased expression
of HOXB4 and NOTCH1 implicated in the self-renewal of
haematopoietic stem cells (Reya et al, 2003). Up-regulation of
the beta-catenin pathway has been suggested in chronic
myeloid leukaemia (CML)-derived granulocyte-macrophage
progenitor cells (GMPs) and multiple myeloma (MM) cells
(Derksen et al, 2004; Jamieson et al, 2004). Furthermore, beta-
catenin reportedly plays a signiﬁcant role in promoting cell
proliferation, adhesion, and survival in vitro (Chung et al,
2002). The expression of beta-catenin is also enhanced by
oncogenic FLT3 signals and associated with poor prognosis
(Tickenbrock et al, 2005; Ysebaert et al, 2006). However, there
are some contradictory reports. Studies of conditional knock-
out mice with a beta-catenin gene (Ctnnb1) deletion indicated
that Ctnnb1 is not indispensable for haematopoiesis (Cobas
et al, 2004). Furthermore, an active form of Ctnnb1 compro-
mised haematopoietic stem cell maintenance and blocked
differentiation in transgenic mice experiments (Simon et al,
2005). The role of the Wnt/beta-catenin pathway in malignant
haematopoiesis therefore needs to be further elucidated.
According to previous studies, the expression of beta-catenin
is associated with activation of the Wnt pathway as well as poor
prognosis (Tickenbrock et al, 2005; Ysebaert et al, 2006).
However,beta-cateninisassociatednotonlywithWntsignaling
but also with adherence junctions (Conacci-Sorrell et al, 2002).
It is anchored to the cell inner surface membrane via cadherins.
In normal bone marrow (BM), the vascular endothelium
expresses a signiﬁcantly higher amount of beta-catenin relative
to the level in haematopoietic cells. Accordingly, immunohis-
tochemical detection of nuclear NPBC would enable a better
understanding of the role of beta-catenin in leukaemia.
This study investigated the subcellular localization of beta-
catenin in BM specimens from acute myeloid leukaemia
(AML) and myelodysplastic syndrome (MDS) patients using
two anti-beta-catenin antibodies: one against C-terminal
peptides and another against N-terminal non-phosphorylated
peptides. The latter antibody detected nuclear NPBC, and
positive staining for nuclear NPBC was associated with
particular clinical characteristics of AML and MDS.
Materials and methods
Patient samples
For clinical samples, BM clots were obtained during routine
diagnostic procedures. Beta-catenin expression was analyzed in
BM specimens from patients newly diagnosed at the Nagoya
University Hospital between 2000 and 2006 (Table I). The
de novoAML patients consisted of 35men and 19women with a
median age of 53 years (range, 20–81 years), and FLT3 muta-
tions were detected in seven of 22 patients with AML (31Æ8%).
The MDS patients consisted of 28 men and 16 women with a
median age of 57 years (range, 22–89 years). BM mononuclear
cells were harvested by standard Ficoll/Paque density gradient
centrifugation (Amersham Pharmacia Biosciences, Roozendaal,
the Netherlands), and were suspended in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 100 IU/ml of
penicillin G and 100 lg/ml of streptomycin.
Antibodies
For immunohistochemical and immunoblot studies, two
monoclonal antibodies were used; one was against C-terminal
peptides (clone14, IgG1; BD Transduction Laboratories/Life
Science Research, Heidelberg, Germany), enabling recognition
of pan beta-catenin (PBC), and the other was against
Table I. Clinical characteristics of AML and MDS patients according
to nuclear NPBC expression.
Nuclear NPBC
+ Nuclear NPBC
- P-value
Patients with
de novo AML
22 32
Age (median) 54 (20–81) 53 (18–71) NS
Sex/male/female 18/4 17/15 0Æ005
Laboratory data
WBC (·10
9/l;
median)
3Æ5( 0 Æ8–92Æ5) 5Æ3( 0 Æ7–202Æ1) NS
Hb (g/l; median) 74 (43–134) 98 (36–141) 0Æ01
PLT (·10
9/l;
median)
7Æ6( 0 Æ3–170) 4Æ2( 1 Æ1–27Æ3) NS
PB blasts (%;
median)
24 (0–82) 39 (0–99) NS
BM blasts (%;
median)
46Æ2 (20–86Æ5) 77Æ5 (29–98) 0Æ02
CR rate 13/22 (59Æ1%) 24/27 (88Æ9%) 0Æ01
Relapse rate 16/21 (76Æ2%) 14/24 (58Æ3%) 0Æ03
Patients with MDS 18 26
Age 59 (26–76) 57 (22–89)
Sex/male/female 12/6 16/10 0Æ05
Laboratory data
WBC (·10
9/l;
median)
2Æ9( 1 Æ2–9Æ0) 2Æ6( 1 Æ6–5Æ9) NS
Hb (g/l; median) 75 (46–151) 85 (47–127) NS
PLT (·10
9/l;
median)
79 (7–122) 44 (7–400) NS
BM blasts (%;
median)
3 (0–30) 5 (0–30) NS
IPSS score*
Low risk 0 4 NS
Intermediate-1 4 12 NS
Intermediate-2 4 4 NS
High risk 3 1 0Æ04
NPBC, non-phosphorylated beta-catenin; AML, acute myeloid leu-
kaemia; MDS, myelodysplastic syndrome; WBC, white blood cell
count; Hb, hemoglobin concentration; PLT, platelet count; PB,
peripheral blood; BM, bone marrow; CR, complete remission; IPSS,
International Prognostic Scoring System.
*Full data was available in 32 of the 44 patients with MDS.
Clinical Signiﬁcance of Beta-catenin in AML and MDS
ª 2008 The Authors
Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 140, 394–401 395N-terminal-peptides (clone 8E4, IgG1; Alexis Biochemicals,
Lausanne, Switzerland), enabling recognition of NPBC.
Immunohistochemical staining
Samples were ﬁxed with ice-cold 4% paraformaldehyde for 16–
24 h, embedded in parafﬁn, sectioned transversely (thickness,
3 lm), and processed for immunohistochemistry to determine
the localization of beta-catenin. After removal of parafﬁn with
xylene and dehydration with a series of ethanol solutions, the
tissuesectionsweresubjectedtomicrowaveirradiation(750 W)
for 15 min in 0Æ01 mol/l citrate buffer (pH 6Æ0). The sections
were then placed in an automated immunostainer (Ventana
Medical Systems, Tucson, AZ, USA) as described (Xu et al,
2002). For negative controls, primary antibodies were replaced
with mouse IgG. The subcellular distribution of beta-catenin
(i.e.restrictiontothenucleusorpresenceinthemembrane)was
assessed without knowledge of the French-America-British
(FAB)subtypes,FLT3mutationsorkaryotypes.Weinvestigated
a single case twice for NPBC expression. The entire section was
screened to ﬁnd the region with the highest immunostaining.
Thescorewasdeterminedineachcaseaftercountingatleast500
nuclei in 3–5 randomly selected regions. When 20% or more of
the BM mononuclear cells were positive for nuclear staining of
NPBC, they were classiﬁed as nuclear NPBC
+. The cut-off value
of 20% was determined by the median distribution of the
percentage of BM mononuclear cells stained by NPBC. As
described in the results, some erythroblasts were positive for
NPBC but the number was <20% except in the case of M6
patients. On the other hand, almost all blasts in M7 and other
cases tested positive. The discrimination of cell types based on
the 20% criterion therefore enabled a clear delineation.
Immunoblotting
Cell lysates from AML cells were extracted as previously
described (Ozeki et al, 2004). A total of 1 · 10
6 cells were
directly lysed in sample buffer and then subjected to sodium
dodecyl sulphate-polyacrylamide gel electrophoresis on a 10%
gel, and the separated proteins were transferred to a polyviny-
lidene diﬂuoride membrane (Bio-Rad, Hercules, CA, USA).
The membrane was initially incubated at room temperaturefor
1 h with 5% nonfat milk and 0Æ1% Tween-20 in Tris-buffered
saline and then overnight with mouse monoclonal antibodies
at a 1:2000 dilution in the same solution. After washing, the
membrane was incubated for 1 h with a 1:5000 dilution of
horseradish peroxidase-conjugated mouse antibodies to mouse
IgG (MBL, Amersham, Bucks, UK), and immune complexes
were then detected with enhanced chemiluminescence (ECL)
reagents (Amersham).
Statistical analysis
The v
2 test was used to calculate the difference of frequencies
between nuclear NPBC
+ and NPBC
) groups. The Mann–
Whitney U-test was used to compare continuous variables.
Kaplan–Meier curves were drawn using statview software
(Macintosh; SAS Institute, Cary, NC, USA). P-values <0Æ05
were considered signiﬁcant.
Results
Using an anti-beta-catenin C-terminal peptide antibody, beta-
catenin was stained in the membrane and cytoplasm of
erythroid cells from normal BM. In de novo AML specimens,
signiﬁcant staining was observed only in M6. This antibody
also detected BM vessels whose density was increased in AML
specimens as previously reported (Serinso ¨z et al, 2004;
Fig 1A). On the other hand, an anti-N-terminal nonphosph-
orylated peptide antibody gave no signiﬁcant staining in the
normal BM. In AML specimens, nuclear NPBC was detected in
erythroid blasts, megakaryoblasts and some myeloblasts
(Fig 1A). In M6 specimens, nuclear NPBC was detected in
30–80% of myelomonocytic cells and nearly 100% of eryth-
roblastic cells (Fig 1A). In M7 specimens, megakaryocytes were
also strongly positive for nuclear NPBC (Fig 1A). In total, 20%
or more of the BM mononuclear cells were positive for nuclear
NPBC in 22 (40Æ7%) of 54 AML patients (Table I, Fig 1B).
There was a strong male predominance of nuclear NPBC
+
cases, comprising 81Æ8% (18/22) in AML patients (Table I).
However, the reason for this is unclear. In our cohort study,
the karyotypes of female patients correlated to t(8;21)/t(15;17),
which did not express nuclear NPBC. Thus the small numbers
of studied patients seem to give some bias to the male
predominance. A large-scale study is necessary to conﬁrm this
association. Nuclear NPBC
+ staining was closely associated
with AML subtype: it occurred frequently (8/9) in M6 and M7
and rarely (0/7) in M3 (Fig 1B), and nuclear NPBC
+ was
preferentially detected in erythroid and megakaryoblastic leu-
kaemia compared to other myeloid leukaemias (M6–M7 vs.
M0–M5, P <0 Æ001).
In MDS specimens, erythroid cells and endothelial cells were
stained with the anti-beta-catenin C-terminal peptide antibody
(Fig 2A). As observed for AML specimens, the cytoplasm and
inner membrane were stained by this antibody. The anti-beta-
catenin N-terminal nonphosphorylated peptide antibody
detected nuclear staining in myeloblasts and erythroblasts that
was similar to the pattern seen in AML cases (Fig 2A). Nuclear
NPBC was found in 18 (40Æ9%) of 44 MDS patients, and was
related to the FAB classiﬁcation of MDS (Table I, Fig 2B).
Nuclear NPBC
+ was preferentially detected in refractory
anaemia with excess blasts in transformation (RAEBT) com-
pared to other MDS subtypes [RAEBT versus refractory
anaemia (RA)/refractory anaemia with ringed sideroblasts
(RARS)/RAEB, P =0 Æ01].
To conﬁrm whether these two antibodies recognized beta-
catenin, a totalof 41samplesfrom AMLand MDSpatients were
subjected to immunoblot analysis. The anti-beta-catenin
C-terminal peptide antibody detected bands at a molecular
weight of 95 kDa, corresponding to beta-catenin, in most
J. Xu et al
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nonphosphorylated peptide antibody gave bands of the same
size in only a few samples of AML and MDS (Fig 3B). The
results of immunoblotting corresponded to those of immuno-
staining, although the latter was more sensitive than the former.
The above ﬁndings suggest that expression of nuclear NPBC
could be used to identify some subsets of AML and MDS. Next
we studied whether nuclear NPBC was associated with
chromosomal abnormalities or genetic alterations. Previous
studies suggested that AML-associated translocations, such as
t(8;21) and t(15;17), contributed to the activation of gamma-
catenin, or that FLT3 mutation might be associated with the
stabilization of beta-catenin. In this study, however, nuclear
NPBC was never detected in AML with t(8;21) or t(15;17). In
AML/MDS with )7/)7q and a complex karyotype, nuclear
NPBC was frequently detected (P =0 Æ007 and P =0 Æ02,
respectively; Table II). Moreover, detection was not related
to FLT3 internal tandem duplication (ITD; Table II).
Finally, we studied whether clinical characteristics and
outcome were different between nuclear NPBC
+ and NPBC
)
AML patients. NPBC
+ AML patients showed signiﬁcantly
lower hemoglobin levels, lower blast percentages in the BM,
and lower CR rates (Table I). There were no signiﬁcant
differences between the NPBC
+ and NPBC
) groups in the
MDS patients (Table I). However, nuclear NPBC was associ-
ated with a high International Prognostic Scoring System
(IPSS) score (Table I). Of note, nuclear NPBC
+ AML patients
had worse overall survival than NPBC
) AML patients (Fig 4A).
Even if the M6/M7 subtype and/or M3 subtype was excluded
from the analysis, there was still a signiﬁcant association
between nuclear NPBC
+ and survival (Fig 4B–D).
Discussion
This study used nuclear NPBC as a biomarker for the activated
Wnt/beta-catenin signaling pathway. The anti-beta-catenin
C-terminal peptide antibody detected total beta-catenin in
immunoblots but mainly cytoplasmic and membrane-associ-
ated beta-catenin in immunohistological analysis, whereas the
anti-beta-catenin N-terminal nonphospholylated peptide anti-
body detected only nuclear beta-catenin in both analyses (data
not shown). Accordingly, it was concluded that the nuclear
staining with the latter antibody identiﬁed nuclear non-
phosphorylated beta-catenin. Nuclear NPBC was detected in
22 (40Æ7%) of 54 AML patients and 18 (40Æ9%) of 44 MDS
patients. Positive staining of nuclear NPBC was associated with
particular AML subtypes (M6 and M7), a low complete
remission rate, and poor prognosis. The presence of nuclear
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Fig 1. Speciﬁc association of NPBC expression with FAB subtypes of AML specimens. (A) In normal BM clots, PBC is expressed on the membranes
of erythroid cells as well as endothelial cells. NPBC was not detected in normal BM clots. Most erythroid cells and endothelial cells showed cell
membrane expression of PBC without expression in the nucleus or cytoplasm. NPBC was expressed in leukemia cells and was always restricted to the
nucleus, especially in M6 and M7 specimens. Prominent staining of endothelial cells was seen in the vascular tissue in BM derived from an M2 patient
with, though NPBC staining was negative in the same specimen. Original magniﬁcation ·40. (B) The graph presents data based on nuclear NPBC
staining in parafﬁn sections from 54 patients with AML.
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with )7/)7q and complex karyotypes.
Previous reports indicated that a signiﬁcant proportion of
AML samples expressed beta-catenin on immunoblot analysis.
The expression of beta-catenin is related to CD34 expression,
poor prognosis and clonogenic capacity ex vivo (Ysebaert et al,
2006). Furthermore, beta-catenin is expressed in normal
CD34
+ progenitor cells and the expression level is reduced
upon differentiation (Simon et al, 2005). In these studies,
however, the total beta-catenin level was analyzed only by
immunoblot analysis. Beta-catenin is expressed not only as
nuclear NPBC but also as a cadherin-associated protein in the
inner cytomembrane (Conacci-Sorrell et al, 2002). The present
study found that normal erythroblasts expressed cytoplasmic
or membrane-associated beta-catenin but not nuclear NPBC
(Fig 1A). Both membrane-associated and nuclear beta-catenin
was expressed in malignant erythroblasts in subtype M6
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Fig 3. Beta-catenin expression of AML cells assessed by immunoblotting. (A) The graph shows data obtained for the expression of NPBC in
mononuclear cells from 41 patients with AML, and the data indicate that expression of NPBC is speciﬁc to some FAB subtypes, especially to M6 and
M7. (B) Representative immunoblots for PBC and NPBC in AML samples. RA, refractory anaemia; RARS, RA with ringed sideroblasts; RAEB, RA
with excess blasts; RAEBT, refractory anaemia with excess blasts in transformation.
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Fig 2. Speciﬁc association of NPBC expression with FAB subtypes of
MDS specimens. (A) Most erythroid cells and endothelial cells showed
cell membrane expression of PBC without expression in the nucleus or
cytoplasm. NPBC was expressed in erythroid cells and was always re-
stricted to the nucleus, especially in refractory anaemia with excess
blasts in transformation (RAEBT) and MDS specimens with )7/)7(q).
Original magniﬁcation ·40. (B) The graph presents data obtained for
nuclear NPBC staining in parafﬁn sections from 44 patients with MDS.
RA, refractory anaemia; RARS, RA with ringed sideroblasts; RAEB, RA
with excess blasts.
Table II. Cytogenetic abnormalities and FLT3 mutation according to
nuclear NPBC expression.
Nuclear
NPBC
+ (N)
Nuclear
NPBC
) (N) P-value
Karyotypes
t(8;21) 0 3 NS
t(15;17) 0 4 NS
)5/)5q 4 1 NS
)7/)7q 12 6 0Æ007
Complex 13 7 0Æ02
Others 19 2 NS
Normal 10 31 0Æ0003
Unknown 7 1 0Æ02
FLT3 mutation
Wild type 3 12 0Æ006
ITD 2 5 NS
Patients are counted more than once due to the coexistence of more
than one cytogenetic abnormality. Complex: patients had three or
more cytogenetic abnormalities.
NPBC, non-phosphorylated beta-catenin; ITD, internal tandem repeat;
NS, not signiﬁcant.
J. Xu et al
ª 2008 The Authors
398 Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 140, 394–401(Fig 1A). These ﬁndings suggest that increased nuclear NPBC
levels were the result of aberrant signal transduction in the
Wnt pathway or an abnormality of beta-catenin itself.
In this study, the expression levels of total and
non-phosphorylated beta-catenin were correlated but varied
signiﬁcantly among leukemia samples. In M6 and M7 samples,
the expression of beta-catenin was signiﬁcantly augmented,
whereas it was hardly detected in M3 and normal BM samples.
These variations suggest the possibility that Wnt/beta-catenin
signaling is mediated by multiple factors, such as immaturity,
lineage, and oncogenic signals.
We established a correlation between nuclear NPBC
+ and
poor survival in AML patients. The prognostic value of total
beta-catenin expression has been previously studied in AML
patients (Ysebaert et al, 2006), but the present study clearly
showed for the ﬁrst time that nuclear NPBC is associated with
prognosis. The association was still observed even if M6/M7
and/or M3 patients were excluded from the analysis. Nuclear
NPBC might be a new prognostic marker for AML and MDS
that can be evaluated by histopathological examination.
Wnts are a family of paracrine and autocrine factors that
regulate cell growth and cell fate (Reya et al, 2003). The Wnt
autocrine signaling mechanism was initially discovered in
human breast and ovarian tumor cell lines as well as in MM
primary samples (Baﬁco et al, 2004; Derksen et al, 2004). Since
several Wnt family members have been reported in BM
stromal cells, it is possible that leukaemia cells respond to
different proteins of the Wnt/beta-catenin pathway secreted by
stromal cells in a paracrine fashion (Austin et al, 1997; Van
Den Berg et al, 1998; Etheridge et al, 2004). Nuclear NPBC was
detected in some cell lines only when they were transplanted in
non-obese diabetic/severe combined immunodeﬁcient/gam-
macnull (NOG) mice (data not shown). Thus, the leukaemia
niche may have an important role in nuclear NPBC expression
during AML.
MDS is a clonal hematopoietic stem cell disorder charac-
terized by multi-lineage dysplasia and pancytopenia in which
further genetic events may be required for the rapid expansion
of leukaemic blasts (Heaney & Golde, 1999; Hirai, 2003).
Although nuclear NPBC has been studied in many cancers as
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MDS (Morin et al, 1997; Barker & Clevers, 2000; Giles et al,
2003). This is the ﬁrst study to report the expression of beta-
catenin in MDS patients. Here we showed that nuclear NPBC
was related to the IPSS score and that secondary AML from
MDS showed the highest percentage of nuclear NPBC
expression. The Wnt signaling pathway may play an important
role in the pathogenesis of the transformation of MDS into
AML. Regarding chromosomal abnormalities, )7/)7q and/or
complex karyotypes were signiﬁcantly associated with the
presence of nuclear NPBC. According to recent data (Liu et al,
2006), the gene encoding alpha-catenin (CTNNA1) is sup-
pressed by deletion and/or methylation. Both alpha-catenin
and beta-catenin bind to the inner membrane of hematopoi-
etic cells, and cadherin binds to actin ﬁlaments via the catenin
complex. If the expression of alpha-catenin is suppressed in the
5q- genotype or for other reasons, beta-catenin may be
abnormally located or activated. In this study, abnormalities of
chromosome 5 were associated with the presence of NPBC but
this was not statistically signiﬁcant. The reason why NPBC is
associated with chromosome 7 abnormalities remains unclear.
A gene encoded by chromosome 7 may be associated with the
regulation of the Wnt/beta-catenin pathway. Several possible
candidate genes including SFRP4, WNT2, and FZD1 and FZD9
are located at human chromosome 7. There are reports that
sFRP4 plays a role in tumor suppression via the Wnt pathway
(Hrzenjak et al, 2004; Horvath et al, 2007), although the
speciﬁc relationship remains unknown. Since many molecules
are directly or indirectly associated with the phosphorylation,
stabilization and nuclear translocation of beta-catenin, the
presence of nuclear NPBC might provide a clue to ﬁnd a new
leukemia-associated signaling mechanism.
In conclusion, in situ detection of nuclear NPBC by
immunohistochemistry of parafﬁn sections from BM speci-
mens could be used to predict the prognosis of AML and MDS.
Understanding the mechanisms leading to leukemogenesis in
nuclear NPBC
+ AML and MDS may lead to new anti-leukemia
therapies.
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